James Tillar

Founder @ Tillar Technologies | Computational Drug Discovery | 56 PRV-Eligible Disease Targets | Constitutional AI Governance.

Haines City, Florida, United States

About

I'm building a system that discovers drugs for diseases the pharmaceutical industry ignores — and does it with constitutional AI governance that makes every prediction auditable, reproducible, and defensible. As Founder and CEO of Tillar Technologies, I designed Predator X: a computational drug discovery platform targeting 56 neglected tropical diseases eligible for FDA Priority Review Vouchers. These are diseases like Nipah, Chagas, and visceral leishmaniasis — conditions that kill hundreds of thousands annually but attract minimal R&D investment because the economics don't work for traditional pharma. The platform uses a constraint-first approach: map the disease geometry, define what a solution looks like, then find molecules that fit. An 8-layer constitutional governance framework ensures no prediction reaches a researcher without passing hard safety thresholds. 2,080 automated tests. Zero failures. 100% deterministic under stress. I publish regularly on constitutional AI, deterministic drug discovery, and invariant-governed systems through my Sovereign Systems newsletter. My work has been shared with Congressional offices and is focused on bridging computational discovery to wet lab validation. The Broken Way Foundation is the parent mission: using technology to serve humanitarian medicine, ethical manufacturing, and crisis response. ORCID: 0009-0005-7669-5683 | Newsletter: Sovereign Systems | GitHub: github.com/TheBrokenWay

Experience